Myelodysplastic Syndrome

• FDA approval · 2017-05-03
  FDA Approved: DECITABINE — Supplemental Application (Dr. Reddy's Laboratories Inc.)

  FDA approves a supplemental ANDA for Dr. Reddy's Laboratories Inc. to market a generic decitabine product.

• FDA approval · 2017-02-27
  FDA Approved: DECITABINE — Original Application (Accord Healthcare Inc.)

  FDA approves an original ANDA for decitabine by Accord Healthcare Inc., establishing a generic version of the drug.

• FDA approval · 2015-02-23
  FDA Approved: VIDAZA — Supplemental Application (Celgene Corporation)

  FDA approved a supplemental application for Vidaza (azacitidine) submitted by Celgene Corporation.

• FDA approval · 2013-05-06
  FDA Approved: VIDAZA — Supplemental Application (Celgene Corporation)

  The FDA approved a Celgene-supplied supplemental application for Vidaza (azacitidine), updating the drug's labeling and/or indications.

• FDA approval · 2010-01-28
  FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for Exjade (deferasirox) from Novartis Pharmaceuticals Corporation.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.